Susmed

Susmed FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Susmed (4263.T) as of Oct 29, 2026 is 143.33 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 146.38 % — a change of -2.08% (lower).

FCF Conversion

143.33 %

YoY

-2.08%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Susmed is 2026 143.33 % . FCF Conversion Rate (FCF/EBITDA) of Susmed was 2025 146.38 % . It decreases by -2.08% lower compared to the previous year.

The Susmed FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
96.15 JPY
Jan 1, 2021
86.29 JPY
Jan 1, 2022
76.19 JPY
Jan 1, 2023
-162.37 JPY
Jan 1, 2024
67.16 JPY
Jan 1, 2025
146.38 JPY
Jan 1, 2026
143.33 JPY
The Susmed FCF Conversion history
YEARFCF ConversionYoY
143.33 %-2.08%
146.38 %+117.95%
67.16 %-141.36%
-162.37 %-313.11%
76.19 %-11.70%
86.29 %-10.26%
96.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Susmed Stock analysis

What does Susmed do? SUSMED, Inc. generates revenue through its DTx Product segment, which develops application software for treating insomnia, breast cancer, and chronic kidney diseases. The DTx Platform segment provides clinical trial systems, machine learning analysis systems, and DTx development support services. The company's primary customers are healthcare providers and pharmaceutical companies seeking digital therapeutics solutions. SUSMED targets the healthcare technology market with its specialized software and support services for disease treatment and clinical research. The DTx Product segment focuses on creating therapeutic applications for specific medical conditions, while the DTx Platform segment offers infrastructure for clinical trials and machine learning analysis. SUSMED's business model relies on selling both its proprietary software products and platform services to healthcare institutions and pharmaceutical firms. The company's revenue streams include software licensing, system subscriptions, and development support fees. SUSMED's products are designed to address chronic conditions like insomnia and breast cancer, with additional focus on chronic kidney diseases. The DTx Platform serves as a comprehensive solution for clinical trial management and machine learning-driven analysis, supporting pharmaceutical companies in their drug development processes. The company's services are tailored to meet the needs of healthcare technology providers and pharmaceutical developers. Susmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Susmed stock

FCF Conversion Rate (FCF/EBITDA) of Susmed is 143.33 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Susmed changed from 146.38 % to 143.33 %, representing a -2.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Susmed since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Susmed with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Susmed

All Key Metrics — Susmed